BetterLife Pharma IncCanadian Securities Exchange:BETRView on OTCQB
- LAST PRICE0.1200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.1200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BETR |
|---|---|---|
| 10:55 ET | 2000 | 0.11 |
| 12:52 ET | 3000 | 0.11 |
| 02:02 ET | 10000 | 0.11 |
| 02:49 ET | 8000 | 0.115 |
| 02:58 ET | 10000 | 0.115 |
| 03:23 ET | 55000 | 0.115 |
| 03:34 ET | 98000 | 0.12 |
| 03:36 ET | 49000 | 0.12 |
| 03:54 ET | 45000 | 0.12 |
| 03:59 ET | 17500 | 0.12 |
May 1, 2024
BetterLife Advances BETR-001 IND-enabling Studies, from 8:00AM ET on Wednesday May 01, 2024 by Dow Jones
8:00AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 11, 2024
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BetterLife Pharma Inc | 13.7M | -5.5x | --- |
Asep Medical Holdings Inc | 14.8M | -1.7x | --- |
Antibe Therapeutics Inc(Pre-Merger) | 15.6M | -0.9x | --- |
Telo Genomics Corp | 10.6M | -3.2x | --- |
Sirona Biochem Corp | 16.6M | -6.2x | --- |
Biovaxys Technology Corp | 16.9M | -0.7x | --- |
Company Information
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.
Contact Information
- Headquarters
- 1275 WEST 6TH AVENUEVANCOUVER, BC, Canada V6H 1A6
- Phone
- 438-884-8841
- Fax
- 604-551-5178
Executives
- Chief Executive Officer, Director
- Ahmad Doroudian
- Chief Financial Officer
- Moira Ong
- Chief Operating Officer of MedMelior
- Hooshmand Sheshbaradaran
- Independent Director
- Robert Metcalfe
- Independent Director
- Ralph Pullen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $13.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 113.8M |
BetterLife Pharma Inc does not pay a dividend. | |
Beta | 1.29 |
EPS | $-0.02 |
Book Value | $-0.12 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
